Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BELIEVE-VHL: Belzutifan in VHL Syndrome
NCT07167329Phase 2Recruiting
- Start
- Jan 2024
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of belzutifan in von Hippel–Lindau disease (VHL). Primary endpoint: Objective Tumor Response per RECIST 1.1 up to 104 weeks. Started Jan 2024; status: recruiting.
02
Drugs
belzutifan
03
Conditions
von Hippel–Lindau disease (VHL)
Beyond the preview
Go deeper on NCT07167329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07167329.